WTX-518, a conditionally activated IL-18 INDUKINE TM molecule that resists suppression by  IL-18BP, led to complete tumor regressions in preclinical models WTX-712, a conditionally activated IL-21 INDUKINE TM molecule has potent antitumor activity in preclinical models with a differentiated

PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc.

–  Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024  – –  WTX-124 recommended dose for expansion (RDE), initiation of monotherapy dose expansion arms and initial combination dose-escalation data also

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the

-  Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINE TM programs anticipated in 2024 - -  WTX-124: updated interim monotherapy dose-escalation data and initial combination dose escalation data from Phase 1/1b clinical trial expected in 1H

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment

–  Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity –    –  Safety data indicate WTX-124 is generally well tolerated through cohort 4 (12 mg), with a wide

Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the